ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Completed · Phase 2

Conditions studied: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining two or more drugs may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of different regimens of ZD9331 with or without topotecan in treating patients who have refractory or recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer.

Key facts

Study ID

NCT00014690

Run by

AstraZeneca

Starts

2001-03-01

Expected to finish

2004-02-01

Last updated by the study team

2013-08-02

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• AstraZeneca Pharmaceuticals LP — Wilmington, Delaware, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.